$0.930
-0.034 (-3.65%)收盘时
OGI 资讯
OGI 事件
Apple Warns of Margin Drop, Mixed Day for Markets
The major averages had a mixed day, with the Dow slipping and the S&P 500 and Nasdaq closing higher, as investors digested another round of corporate earnings reports. Apple slid after warning of lower margins and Palantir moved lower despite strong Q3 growth. Today's U.S. midterm elections are also top of mind given the possibility that Democrats could take control of the Senate and House of Representatives.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q4 results but forecast a Q1 margin drop, warning that rising memory chip costs will cause some pressurePalantirprovided a "beat and raise" report for Q3Pfizeralso provided a "beat and raise" report for Q3 and named Cecile Guegan as CFOCVR Energyagreed to acquire two refineries and the marketing platform from Marathonfor $4.2BDisneyis considering eliminating thousands of jobs, Bloomberg reports2. WALL STREET CALLS:Barclays upgraded Bloom Energyto Overweight on ramping demandD.R. Hortondowngraded to Underperform at Raymond JamesJPMorgan upgraded Cloudflareto Overweight on valuation after selloffMarvelldowngraded at BofA and TD Cowen on Lumentumdeal overhang and sector contractionGoldman upgraded SiriusXMto Buy on spectrum holdings, YouTube ads deal3. AROUND THE WEB:U.S. officials have held up clearance for American chipmaking equipment that SK Hynixneeds to expand output in China, Reuters reportsMetais weighing raising at least $20B through its first major bond sale in six months and its debut euro offering, with dollar maturities spanning five to 30 years and euro maturities extending beyond 38 years, as it tests debt market appetite amid growing scrutiny of AI spending, Bloomberg reportsNvidiais instructing its data center partners to reduce exposure to Chinese customers, telling them to sell at least 51% of their services to non-Chinese companies, FT saysSamsungis planning to use its plant in Taylor, Texas to make base dies for high-bandwidth memory chips for both AMDand Nvidia, Reuters reportsTesla'sChina-made EV sales grew in October, with deliveries of Model 3 and Model Y vehicles produced at its Shanghai plant rising 10.3% year-over-year to 67,829 units in October, Reuters reports4. MOVERS:Aurora Cannabisgained in New York after announcing it will be acquired by Organigramfor C$7.80 per shareAehr Test Systemsincreased after reporting Q1 results and narrowing its guidance for FY27Beta Technologiesand Graphic Packagingwere higher after reporting quarterly resultsStevanato Groupwas lower in New York after reporting Q3 results and reaffirming guidance for FY26Adeiaand Dynatracefell after reporting quarterly results5. EARNINGS/GUIDANCE:HNI Corporationreported Q3 results, with EPS beating consensusTalen Energyreported Q3 results, backed its guidance for FY26, and provided guidance for FY27Fiservreported Q3 results, with EPS and revenue beating consensusKeurig Dr Pepperreported Q3 results and provided guidance for FY26CVR Energyreported Q3 results, with EPS and revenue beating consensusINDEXES:The Dow fell 197.26, or 0.38%, to 51,786.72, the Nasdaq gained 207.65, or 0.83%, to 25,372.01, and the S&P 500 advanced 27.52, or 0.36%, to 7,568.92.
Apple Warns of Margin Drop, Markets Mixed
The major averages were mixed near noon, with the Dow fractionally lower but the S&P 500 and Nasdaq higher, as investors digest the latest spate of corporate earnings reports. Apple is slipping after warning of lower margins and Palantir is moving lower despite strong Q3 growth. Today's U.S. midterm elections are also top of mind given the possibility that Democrats could take control of the Senate and House of Representatives.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q4 results but forecast a Q1 margin drop, warning that rising memory chip costs will cause some pressurePalantirprovided a "beat and raise" report for Q3Pfizeralso provided a "beat and raise" report for Q3 and named Cecile Guegan as CFOCVR Energyagreed to acquire two refineries and the marketing platform from Marathonfor $4.2BDisneyis considering eliminating thousands of jobs, Bloomberg reports2. WALL STREET CALLS:Barclays upgraded Bloom Energyto Overweight on ramping demandD.R. Hortondowngraded to Underperform at Raymond JamesJPMorgan upgraded Cloudflareto Overweight on valuation after selloffMarvelldowngraded at BofA and TD Cowen on Lumentumdeal overhang and sector contractionGoldman upgraded SiriusXMto Buy on spectrum holdings, YouTube ads deal3. AROUND THE WEB:Metais weighing raising at least $20B through its first major bond sale in six months and its debut euro offering, with dollar maturities spanning five to 30 years and euro maturities extending beyond 38 years, as it tests debt market appetite amid growing scrutiny of AI spending, Bloomberg reportsNvidiais instructing its data center partners to reduce exposure to Chinese customers, telling them to sell at least 51% of their services to non-Chinese companies, FT saysSamsungis planning to use its plant in Taylor, Texas to make base dies for high-bandwidth memory chips for both AMDand Nvidia, Reuters reportsAdvocate General Maciej Szpunar, an adviser to the Court of Justice of the European Union, said Google'suse of press stories in its Gemini chatbot when responding to queries may infringe copyright rules in certain circumstances, Reuters reportsTesla'sChina-made EV sales grew in October, with deliveries of Model 3 and Model Y vehicles produced at its Shanghai plant rising 10.3% year-over-year to 67,829 units in October, Reuters reports4. MOVERS:Aurora Cannabisgains in New York after announcing it will be acquired by Organigramfor C$7.80 per shareAehr Test Systemsincreases after reporting Q1 results and narrowing its guidance for FY27Beta Technologiesand Graphic Packaginghigher after reporting quarterly resultsStevanato Grouplower in New York after reporting Q3 results and reaffirming guidance for FY26Adeiaand Dynatracefalls after reporting quarterly results5. EARNINGS/GUIDANCE:HNI Corporationreported Q3 results, with EPS beating consensusTalen Energyreported Q3 results, backed its guidance for FY26, and provided guidance for FY27Fiservreported Q3 results, with EPS and revenue beating consensusKeurig Dr Pepperreported Q3 results and provided guidance for FY26CVR Energyreported Q3 results, with EPS and revenue beating consensusINDEXES:Near midday, the Dow was down 218.72, or 0.42%, to 51,765.26, the Nasdaq was up 221.07, or 0.88%, to 25,385.44, and the S&P 500 was up 35.27, or 0.47%, to 7,576.67.
Organigram to Acquire Aurora Cannabis for C$7.80 per Share
Organigram to acquire Aurora Cannabis for C$7.80 per share
Organigram to Acquire Aurora at C$7.80 per Share, Valuing Transaction at Approximately C$561 Million
Organigram Global (OGI) and Aurora Cannabis (ACB) announced that they have entered into an arrangement agreement pursuant to which Organigram will acquire all of the issued and outstanding common shares of Aurora at a price of C$7.80 per Aurora Common Share. The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings (CURLF) of its intention to launch a hostile takeover bid for Aurora, and a 21% premium relative to the current bid value of the Curaleaf hostile offer as most recently amended on October 6, 2026, which was unanimously rejected by Aurora's Board of Directors. The Transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company. Together, Organigram and Aurora will create a global cannabis champion with a leadership position in Canada, Europe and Australia and a growing presence across other key regions. The two Canadian-headquartered cannabis companies will boast a global platform with greater scale, broader capabilities, financial strength and international reach. Organigram's recreational cannabis leadership, production network, R&D platform and European medical commercial operations complement Aurora's global medical cannabis leadership, established international presence, and EU-GMP certified manufacturing capabilities. The combined company will also benefit from the support of Organigram's cornerstone strategic shareholder, BT DE Investments Inc., a wholly-owned indirect subsidiary of British American Tobacco, a global consumer goods company with demonstrable innovation, marketing and product development capabilities around the world. In excess of C$50M in identified synergies from cross-selling across Organigram's and Aurora's Canadian and international footprints, procurement scale, consolidated distribution, public company expenses, and routing international demand to the lowest-cost production asset across the combined network. The acquisition will result in a larger market capitalization and increased free float. Index eligibility is expected to broaden the institutional shareholder base and support improved trading liquidity and research coverage. Greater scale, certified international supply and a diversified revenue base will make the combined entity the clear strategic counterparty in the sector for global CPG and pharmaceutical partners. Aurora shareholders are expected to hold approximately 35% pro forma economic ownership of the combined company on a fully diluted basis and 42% voting ownership, ensuring a meaningful opportunity to participate in the combined company's future growth and value creation. Under the terms of the Arrangement Agreement, Aurora shareholders will have the option to elect to receive: C$7.80 per Aurora Share in cash; 5.8626 common shares in the capital of Organigram per Aurora Share; or a combined consideration of C$3.75 in cash plus 3.0431 Organigram Shares, in each case per Aurora Common Share. Aurora shareholders electing to receive the Cash Consideration or the Share Consideration will be subject to proration as set out in the Arrangement Agreement so that the aggregate consideration will include no more than 205,826,172 Organigram Shares and no more than C$253,638,772 in cash. Based on the 20-day volume-weighted average trading price of Organigram Shares on the TSX of approximately C$1.33 on November 2, 2026, the Consideration represents C$7.80 per Aurora Common Share. The Transaction will be carried out by way of a court-approved plan of arrangement under the Business Corporations Act and is subject to the following approvals: At least two-thirds of the votes cast by Aurora shareholders present in person or represented by proxy at a special meeting of Aurora shareholders; and A simple majority of the votes cast by Aurora shareholders present in person or represented by proxy at the Aurora Meeting, excluding votes from certain shareholders, as required under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The issuance of Organigram Shares pursuant to the Transaction and Private Placement is subject to the approval by a simple majority of votes cast by Organigram shareholders at a special meeting of Organigram shareholders, excluding votes held by BAT, as required under MI 61-101 and the rules of the TSX. Details of the Transaction and the required shareholder votes will be included in a joint information circular that Organigram and Aurora expect to mail to their respective shareholders in due course. The special meetings for Organigram shareholders and Aurora shareholders are expected to be held in December 2026. BAT, which is entitled to cast 30% of the votes attaching to Organigram Shares, has entered into an irrevocable voting agreement agreeing to vote its Organigram Shares in favour of the Transaction and against any competing acquisition proposals. The voting agreement with BAT will not be terminable until six months following termination of the Arrangement Agreement in certain circumstances. In addition, each of the other directors and officers of each of Aurora and Organigram have entered into customary voting agreements agreeing to vote their Aurora Shares or Organigram Shares in favour of the Transaction. The voting and support agreements with directors and officers will terminate automatically upon termination of the Arrangement Agreement. In addition to the shareholder approvals, the Transaction will be subject to regulatory approvals, as well as the approval of the Supreme Court of British Columbia. Subject to the satisfaction of such conditions, the Transaction is expected to be completed in January 2027.
Organigram Holdings Trading Halted, News Pending
Organigram Holdings trading halted, news pending
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。